ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial performance with a 28.4% revenue increase and improved margins. Optimistic guidance on manufacturing capacity expansion and strategic focus on the First Defense line further support a positive outlook. Despite challenges in international market entry and increased operating expenses, the growth in domestic sales and effective capacity management are promising. Q&A insights on product differentiation and sales strategy reinforce confidence. Overall, the sentiment is positive, likely leading to a 2% to 8% stock price increase.
Key Financial Performance
Revenue $10.4 million for Q1 2026, an increase of 28.4% year-over-year. Domestic sales grew 35.7% to $9.7 million, while international sales declined 30.2% to $600,000. The increase in revenue is attributed to strong sales of Tri-Shield and improved manufacturing capacity.
Gross Margin 45% in Q1 2026, up from 41.6% in Q1 2025. The improvement is due to price realization and manufacturing performance, partially offset by a 2.4% headwind from former Re-Tain-related costs.
Net Income $1.9 million in Q1 2026, a 34% increase from $1.4 million in Q1 2025. The growth is driven by higher revenue and improved gross margins.
Operating Expenses $2.7 million in Q1 2026, up from $2.2 million in Q1 2025. The increase is due to higher G&A expenses related to leadership investments and increased sales expenses, partially offset by lower product development expenses.
EBITDA $2.6 million in Q1 2026, up from $2.3 million in Q1 2025. The improvement reflects higher revenue and gross margin expansion.
Cash on Hand $6.8 million as of March 31, 2026, an improvement from year-end 2025 due to strong product sales.
Working Capital $15 million as of March 31, 2026, up from $13 million at the end of 2025, driven by robust sales performance.
Manufacturing Output 450,000 units per month in Q1 2026, up from 380,000 units per month in 2025. The increase is due to improved planning, reduced waste, and incremental investments in equipment.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
First Defense: Focus on First Defense, a leading calf scours preventative product, has shown significant results. Tri-Shield, part of this product line, grew 38.5% in Q1 2026 compared to Q1 2025. First Defense provides immediate protection for newborn calves against common pathogens and offers additional bioactives derived from colostrum.
Domestic Market Expansion: Domestic sales grew 35.7% in Q1 2026 compared to Q1 2025, reaching $9.7 million. The company expanded U.S. sales territories by three due to strong domestic momentum.
International Market: International sales declined 30.2% to $600,000 in Q1 2026. However, the company is transitioning to a strategic approach for international opportunities, focusing on market prioritization and capacity expansion.
Manufacturing Capacity: Manufacturing output reached a record of over 450,000 units per month in Q1 2026, up from 380,000 units in 2025. Improvements included better planning, reduced waste, and incremental investments in equipment.
Gross Margin Improvement: Gross margin increased to 45% in Q1 2026 from 41.6% in Q1 2025, driven by price realization and manufacturing performance.
Strategic Focus Shift: In late 2025, the company shifted its focus to First Defense, discontinuing development of Re-Tain. This decision aligns with the growing market for calf scours prevention.
Capacity Expansion Plans: Plans to expand colostrum processing capacity using advanced equipment and assets from the discontinued Re-Tain project. A $2 million settlement with a former contract manufacturer will fund this expansion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Manufacturing capacity constraints: The company has faced challenges in manufacturing capacity and product availability, which have historically impacted its ability to meet market demand. Efforts are ongoing to address these constraints, but they remain a critical focus area.
Contamination risk in manufacturing: The company must manage and mitigate contamination risks in its manufacturing processes to ensure product quality and availability.
Supply chain management: Maintaining great service to colostrum-supplying farms is essential, and disruptions in this supply chain could adversely impact production.
Yield improvement challenges: Improving manufacturing yield is a complex process requiring consistent daily efforts, and failure to sustain these improvements could impact operational efficiency and profitability.
Capacity expansion execution: The company is executing a major capacity expansion in its colostrum processing plant, which involves significant planning and investment. Any delays or issues in this expansion could hinder the ability to meet long-term demand.
International market entry risks: While the international market presents significant opportunities, success requires disciplined market prioritization, regulatory compliance, and strategic execution, which could pose challenges.
Increased operating expenses: Operating expenses have risen due to investments in leadership and expanded commercial activities, which could pressure margins if not managed effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company achieved a record $10 million in product sales in Q1 2026, with Tri-Shield showing strong growth. The U.S. scours biologics category grew 11% year-over-year in Q1 2026, and ImmuCell's First Defense accounted for nearly 80% of the total category dollar expansion.
Market Share Expansion: ImmuCell's share of U.S. category spend expanded from 29.1% to 35.2%, and its share of animals treated increased from 15% to 18.1% between 2021 and Q1 2026. The company aims to capture more of the addressable U.S. market, estimated at over $200 million, and sees international opportunities as at least 5x larger.
Manufacturing Capacity: The company increased manufacturing output to over 450,000 units per month in Q1 2026, up from 380,000 units per month in 2025. Plans are underway to expand capacity further using advanced process flows and state-of-the-art equipment.
International Expansion: ImmuCell is transitioning to a strategic approach for international opportunities, focusing on market prioritization, regulatory activity, and capacity expansion timelines. The company sees significant potential in international markets.
Capital Deployment: A $2 million settlement with a former contract manufacturer will be used to expand manufacturing capacity to meet long-term demand.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you talk about your First Defense in bulk product, its seasonality, target market, and whether it competes with existing products?
A:The First Defense bulk product is a non-USDA-approved product using a different manufacturing process but incorporates First Defense technology. It reduces manufacturing costs and is offered at a lower price point. It is suitable for operations feeding calves as a group rather than individually. The product was launched in the second half of last year and is still in the product launch phase.
Q:What were the key improvements that led to yield improvement, and what is your current maximum capacity with your 4 freezers?
A:Key improvements included better planning by aligning sales and production forecasts, adding overtime capacity to critical manufacturing steps, reducing waste, and making minor capital investments to address bottlenecks. The company is continuously improving yields and does not have a specific maximum capacity number. They are also actively planning a major capacity expansion.
Q:What drove the trajectory of Tri-Shield, including its dip in 2025 and rebound?
A:The trajectory was influenced by backorder dynamics, which affected product availability. Tri-Shield is the flagship product and has seen growth as more customers shift to it. It is a premium-priced product, and its uptake was driven by high demand in the least price-sensitive segment during the recent calving season.
Q:What are the main drivers of your sales force expansion, and how is it divided regionally and by target market?
A:The sales force expansion aims to cover the entire country, targeting both dairy and beef markets. Growth is seen in both segments, with significant increases in beef due to rising calf values. The strategy focuses on increasing customer contact to educate them about the product's differentiation, leading to more revenue. A third territory in the western U.S. was added to accelerate hiring and optimize sales cycles based on regional calf populations and treatment rates.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses provided detailed and specific information.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Defense calf
Diaz
GA investment
ImmuCell conference
ImmuCell result
Shield flagship
Tain cost
Tain increase
activity pace
asset cost
assist investor
availability size
backorder period
balance sheet
basis charge
calf market
calf prevention
calf product
call rationale
capacity product
challenge market
challenge result
change success
charge income
company ImmuCell
conference result
cost good
demand manufacturing
development cost
development expense
development shift
discussion income
end
financials
product development
shift Tain
ICCC Transcript
ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
Positive5-15
The earnings call reflects strong financial performance with a 28.4% revenue increase and improved margins. Optimistic guidance on manufacturing capacity expansion and strategic focus on the First Defense line further support a positive outlook. Despite challenges in international market entry and increased operating expenses, the growth in domestic sales and effective capacity management are promising. Q&A insights on product differentiation and sales strategy reinforce confidence. Overall, the sentiment is positive, likely leading to a 2% to 8% stock price increase.
ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call presents mixed signals: improved gross margins and domestic sales growth are positive, but supply constraints, competition, and declining international sales offset this. The Q&A reveals management's evasiveness on recurring revenue, raising concerns. Despite operational improvements and no large future write-downs, the lack of guidance on recurring revenue and international market underdevelopment tempers optimism. The neutral sentiment reflects these balanced positives and negatives, with no strong catalysts to drive significant stock movement.
ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call presents a mixed picture: improved gross margins and domestic sales growth are positive, but international sales decline and regulatory delays pose risks. The Q&A highlights effective inventory management and customer engagement, but challenges in supply chain and competitive pressures remain. Despite financial improvements, the lack of new partnerships or strong guidance tempers optimism. Overall, the sentiment is neutral, as positives are balanced by uncertainties.
ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript
Positive8-15
The earnings call indicates strong financial performance with record revenue growth, improved EBITDA, and a better cash position. Challenges remain, such as FDA approval delays for Re-Tain and strategic partner needs, but management is addressing them. The reduction in backlog and net debt, coupled with a focus on First Defense expansion, are positive signs. The market is likely to react positively, considering the company's strategic initiatives and recent financial achievements, despite some uncertainties.
ICCC Slides
ICCC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
